BTG plc Appoints Dr John Brown as Chairman Designate

BTG plc Appoints Dr John Brown as Chairman Designate

BTG plc Appoints Dr John Brown as Chairman Designate

London, UK, 4 December 2007: BTG plc (LSE: BGC), the life sciences company, today announces the following Board changes.

Dr John Brown is to join the Board of BTG on 1 January 2008 as a non-executive director and, upon the retirement of Sir Brian Fender on 3 March 2008, will become non-executive Chairman of BTG.

Sir Brian Fender commented:

“I am delighted that John Brown will join our board and will succeed me as Chairman of BTG. I have enjoyed the years I have spent as a director and then Chairman of this exciting company and wish John every success in moving BTG forward in the coming years.”

John Brown, PhD MBA FRSE is a non-executive director of a number of public and private biotech companies including Ardana plc, Protherics plc and Vectura Group plc, and was a director of Cambridge Antibody Technology plc until its recent acquisition by AstraZeneca. He currently chairs the Governing Council of the Roslin Institute in Edinburgh and is chairman of Scottish Biomedical, CXR Ltd and SingVax Pte Ltd. He sits on the advisory board of the Life Sciences ITI in Scotland, is a member of the UK Technology Strategy Board and an advisor to several private equity and venture capital funds.

Until late 2003, Dr Brown was Chief Executive of Acambis plc, a leading producer of vaccines to treat and prevent infectious disease. John holds a PhD in neuropharmacology from Edinburgh University and is a Fellow of the Royal Society of Edinburgh.

There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Services Authority Listing Rules.

For further information contact:

Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; mobile: +44 (0)7990 530605

Christine Soden, Chief Financial Officer
+44 (0)20 7575 1591

Financial Dynamics
Ben Atwell
+44 (0)20 7831 3113

About BTG
BTG in-licenses, develops and commercialises pharmaceuticals principally in the areas of neuroscience and oncology. The company has a substantial and growing revenue stream of royalties from out-licensed products and a broad, expanding internal pipeline of development programmes. BTG operates from offices in London, Philadelphia and Osaka. For further information, visit:

Back to press releases